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Hypoxia as a target for drug combination therapy of
liver cancer
Cressida Bowyera, Andrew L. Lewisb, Andrew W. Lloyda, Gary J. Phillipsa and
Wendy M. Macfarlanea
Hepatocellular carcinoma (HCC) is the third most frequent
cause of cancer deaths worldwide. The standard of care for
intermediate HCC is transarterial chemoembolization,
which combines tumour embolization with locoregional
delivery of the chemotherapeutic doxorubicin. Embolization
therapies induce hypoxia, leading to the escape and
proliferation of hypoxia-adapted cancer cells. The
transcription factor that orchestrates responses to hypoxia
is hypoxia-inducible factor 1 (HIF-1). The aim of this work is
to show that targeting HIF-1 with combined drug therapy
presents an opportunity for improving outcomes for HCC
treatment. HepG2 cells were cultured under normoxic and
hypoxic conditions exposed to doxorubicin, rapamycin and
combinations thereof, and analyzed for viability and the
expression of hypoxia-induced HIF-1α in response to these
treatments. A pilot study was carried out to evaluate the
antitumour effects of these drug combinations delivered
from drug-eluting beads in vivo using an ectopic xenograft
murine model of HCC. A therapeutic doxorubicin
concentration that inhibits the viability of normoxic and
hypoxic HepG2 cells and above which hypoxic cells are
chemoresistant was identified, together with the lowest
effective dose of rapamycin against normoxic and hypoxic
HepG2 cells. It was shown that combinations of rapamycin
and doxorubicin are more effective than doxorubicin alone.
Western Blotting indicated that both doxorubicin and
rapamycin inhibit hypoxia-induced accumulation of HIF-1α.
Combination treatments were more effective in vivo than
either treatment alone. mTOR inhibition can improve
outcomes of doxorubicin treatment in HCC. Anti-Cancer
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the third most common cause
of cancer-related deaths [1]; it is often diagnosed at
an intermediate or an advanced stage, when treatment
options are limited and the prognosis is poor.
Transarterial chemoembolization (TACE) using the
anthracycline antibiotic doxorubicin is the standard
treatment for unresectable intermediate HCC [2]. TACE
combines embolization with locoregional delivery of
chemotherapeutic agent(s). HCCs are typically highly
vascularized [3] and embolization therapies for HCC
exploit the fact that the liver tumour is fed by the hepatic
artery, whereas the normal liver tissue is fed mainly by
the portal vein [4]. Disruption of the arterial blood supply
results in a depletion of oxygen and nutrients to the
tumour cells, and consequent necrosis and tumour
shrinkage. Drug-eluting bead transarterial chemoembo-
lization (DEB-TACE) is a refinement of TACE and
provides a one-step procedure for both embolization and
drug delivery. DEB-TACE enables a controlled, loca-
lized and sustained release of the drug to the tumour bed,
with reduced systemic doxorubicin and an improved
safety profile compared with cTACE [5–7]. Currently,
the most widely used and studied DEB is DC Bead, a
sulphonate-modified polyvinyl alcohol hydrogel micro-
sphere system that can be conveniently loaded in the
hospital pharmacy with cationic drugs such as doxor-
ubicin hydrochloride [8]. Once the drug has been fully
sequestered into the beads by an ion-exchange process, it
is delivered to the interventional radiologist and admi-
nistered through the hepatic arterial vasculature to the
site of the tumour, where the drug is then released in a
controlled and sustained manner over the next weeks. A
feature of the embolization of the blood vessels is the
generation of ischaemia, which is the primary cause of
tumour cell death following this procedure, but that also
may have downstream ramifications.
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Tumour hypoxia is a feature of all solid tumours, and is a
requirement for tumour growth [9]. Intratumoural hypoxia
and the hypoxic phenotype are implicated in therapy
resistance, tumour malignancy, tumour progression and a
poor prognosis. A negative, but inevitable, consequence of
embolization therapy is the de novo formation of hypoxic
regions within the tumour. Hypoxic tumour cells undergo
phenotypic adaptations that allow the cells to survive and
results in the clonal selection of refractory tumour cells
[10]. The transcription factor, hypoxia-inducible factor 1
(HIF-1) is the master regulator of cellular responses to
hypoxia. HIF-1 is a heterodimeric DNA-binding complex
consisting of α and β subunits. The HIF-1α subunit is
subjected to oxygen-dependent post-translational degra-
dation by hydroxylation of prolyl residues within the
oxygen-dependent degradation domain, which promotes
the interaction of HIF-1α with the von Hippel–Lindau
tumour-suppressor protein, a component of the
protein–ubiquitin ligase complex that targets HIF-1α for
rapid degradation. Under hypoxic conditions, HIF-1α
stabilizes and translocates to the nucleus, where it het-
erodimerizes with HIF-1β. The HIF-1 complex binds to
hypoxia response elements present in the enhancer or
promoter regions of the HIF-1 target gene [11]. The
transcriptional activity if HIF-1 is subjected to oxygen-
dependent regulation, whereby the asparagyl hydroxylase
factor inhibiting HIF-1 (FIH-1) blocks the association of
transcriptional coactivators CREB (cAMP response ele-
ment binding)-binding protein/p300 with the C-terminal
transactivation domain of HIF-1α in the presence of
oxygen [12]. Clinical and animal studies have reported
increased HIF-1α after TACE in both plasma and tumour
samples [13–15]. The genes regulated by HIF-1 enable
the cells to survive in a hypoxic environment and thus
promote tumour growth [16].
The cytotoxicity of doxorubicin against cancer cells is
attributed to the intercalation of the drug in the DNA of
dividing cells; the induction of topoisomerase-II-mediated
strand breaks; and the generation of oxygen radicals that
damage DNA and cell membranes [17–19]. Recent data
suggest that doxorubicin inhibits the transcription of HIF-
mediated genes by blocking the binding of HIF-1 to the
promoter region of hypoxia response genes [20].
Rapamycin interferes with the PI3K/Akt/mTOR signal-
ling pathway, a pathway that is known to play an
important role in cancer progression and is known to be
deregulated in around half of all HCCs [21]. Activation of
mTOR (mechanistic target of rapamycin) increases the
rate of translation of HIF-1α [22]. The mTOR inhibitor
rapamycin has been shown to exert antitumoural effects
in vitro and in vivo [23–30]. In addition to the use of
either doxorubicin or rapamycin against HCC, there is
also potential for the use of both in combination. Drugs
that target molecular pathways exert their effects on
stromal tissues and cells and the processes that support
tumour growth, as well as on tumour cells themselves.
Rapamycin and doxorubicin have been shown to have
additive effects in vivo in murine models of liver, pros-
tate, cervical and lung cancers [31–33].
The majority of in-vitro investigations are carried out at
ambient (21%) oxygen, and do not properly model
in-vivo intratumoural physiology, wherein oxygen con-
centrations are likely to be much lower [34]. To under-
stand the biology of cells occupying hypoxic niches,
in-vitro research needs to be carried out at physiologi-
cally relevant oxygen concentrations. Increased under-
standing of the pathophysiological responses to hypoxia
will contribute towards improved treatment regimens and
better outcomes for patients.
Here, we established a hypoxic model of HCC by culti-
vating HepG2 cells at 1% oxygen. The time-dependent
and concentration-dependent effects of doxorubicin,
rapamycin and both drugs in combination on the viability
of HepG2 cells were investigated under both normoxic
and hypoxic culture conditions. SDS-PAGE and Western
Blotting were then used to evaluate the responses of
hypoxia-induced HIF-1α after application of the same
chemotherapeutics. Finally, the antitumour effects of
DEBs loaded with doxorubicin, rapamycin and both
drugs in combination were investigated in vivo using an
ectopic xenograft murine model of HCC.
Materials and methods
Cell lines
HepG2 cells were obtained from the American Type
Culture Collection (Rockville, Maryland, USA) and cul-
tured as recommended by the supplier. Cells were
maintained in minimum essential medium+Earle’s
salts+ L-glutamine, supplemented with 10% foetal
bovine serum heat-inactivated and 1% nonessential
amino acids (all from PAA Laboratories, GmBH, Cölbe,
Germany). For hypoxic incubations (1% oxygen), the
cells were cultured in a hypoxic glove box (COY
Laboratory Products Inc., Grass Lake, Michigan USA).
Cell viability assay
HepG2 cells were seeded onto 96-well plates (1× 104
cells/well in 200 µl aliquots) and incubated overnight.
Plates were exposed to doxorubicin (Zhejiang Hisun
Pharmaceuticals, Zhejiang, China), rapamycin (LC
Laboratories, Woburn, Massachusetts, USA) or a combi-
nation of both and incubated for 24, 48 and 72 h under
normoxic or hypoxic conditions (six replicate wells for
each drug concentration). Cell viability was assessed using
the 3-(4, 5 dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4 sulphophenyl) 2H-tetrazolium, inner salt
(MTS) cytotoxicity assay (Promega, Southampton, UK)
according to the manufacturer’s instructions.
Western blot analysis
Cells were harvested and nuclear extracts were prepared.
Overall, 20 µg of protein (as determined by Bradford assay)
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was resolved on a 10% polyacrylamide gel and transferred to a
polyvinylidene fluoride membrane (Immobilon-Pmembrane;
Millipore Corp., Watford, Hertfordshire). Immunoblotting
was carried out using antibodies against HIF-1α (Cell
Signalling Technology, Danvers, Massachusetts, USA) and
Lamin B1 (Abcam, Cambridge, UK). Protein was detected
and quantified using chemiluminescence (Amersham ECL
Plus Western Blotting Detection Reagents; GE Healthcare,
Buckinghamshire, UK) and FlouroChem software (Alpha
Innotech; San Leandro, California, USA); the target protein
was normalized to a house-keeping protein control.
Immunohistochemistry
HepG2 cells were seeded onto chamber slides (Fisher
Scientific, Leicestershire, UK) and incubated under
normoxic conditions until confluence was 60%. The cells
were then incubated in either 21% oxygen or 1% oxygen
for 24 h and fixed with 3.7% formalin. The cells were
incubated overnight with antibodies to HIF-1α, and
then incubated with tetramethylrhodamine-5-(and 6)-
isothiocyanate fluorescein isothiocyanate conjugated
secondary antibody. 4′,6-Diamidino-2-phenylindole stain-
ing was used to visualize the nucleus. Images are taken at
× 100 magnification.
Ectopic xenograft murine model of hepatocellular
carcinoma
Experiments were conducted by EPO-GmbH and
approved by LAGeSo (State Office of Health and Social
Affairs), Berlin. National Medical Research Institute nu/
nu mice (Taconic M&B, Ry, Denmark), adult females of
20 g were randomly assigned to treatment groups. In all,
1× 107 HepG2 cells from the culture were transplanted
subcutaneously at day 0. Treatment started when
tumours were of palpable size. DC Bead microspheres
(Biocompatibles UK Ltd, Camberley, UK) were loaded
to a doxorubicin concentration of 25mg/ml, a rapamycin
concentration of 20 mg/ml and a combination of both as
described previously [35]. The beads were lyophilized
and gamma sterilized (Isotron PLC, Wiltshire, UK). A
3 ml aliquot of alginate solution (CellMed Ag, Alzenau,
Germany) was added to a vial containing 1 ml of beads
and mixed. Overall, 100 μl of bead/alginate mix was
applied adjacent to the tumour by direct injection. For
oral administration, rapamycin powder was dissolved in
ethanol to a concentration of 10 mg/ml and diluted to
0.01 mg/ml in drinking water. A dose of 1 mg/kg/day was
administered by gavage. Tumour growth was measured
twice per week in two perpendicular diameters using a
calliper. Tumour volume was calculated using the ellip-
soid volume formula (volume= π/6× length×width2).
The mice were inspected for signs of toxicity and beha-
vioural changes immediately after application of the
beads and then twice daily. Body weight change was
used as a parameter for toxicity and was determined twice
per week. Mice were euthanized at a moribund stage or if
the tumour was larger than 10% of the total body weight.
The tumours were excised and weighed postmortem.
Results
The effects of doxorubicin, rapamycin and combinations
on cell viability under normoxic and hypoxic conditions
To determine the effect of doxorubicin, rapamycin and
combinations of both on HepG2 cell viability, a series of
time-dependent and concentration-dependent MTS
assays were carried out. The effects of doxorubicin alone
are summarized in Fig. 1a. After 48 h (Fig. 1a), 10, 25 and
50 µmol/l doxorubicin treatments all reduced the viability
of HepG2 cells cultured under normoxic conditions
(P= 0.000, 0.002 and 0.004, respectively). The 10 µmol/l
treatment was not significantly more effective than either
the 25 or the 50 µmol/l treatments (P= 0.126 and 0.648,
respectively). After 72 h, 10, 25 and 50 µmol/l doxorubicin
treatments all reduced the viability of HepG2 cells cul-
tured under normoxic conditions (P= 0.000, 0.001 and
0.010, respectively). The 10 µmol/l treatment was not
significantly more effective than either the 25 or the
50 µmol/l treatments (P= 0.993 and 1.000, respectively).
The hypoxic cells were more resistant to doxorubicin
treatment. After 48 h, only the 10 µmol/l treatment sig-
nificantly reduced the cell viability of HepG2 cells cul-
tured under hypoxic conditions (P= 0.005); treatments of
25 and 50 µmol/l had no significant effect (P= 0.280 and
0.546, respectively). After 72 h, only the 10 µmol/l treat-
ment significantly reduced the cell viability of HepG2
cells cultured under hypoxic conditions (P= 0.001);
treatments of 25 and 50 µmol/l had no significant effect
(P= 0.288 and 0.065, respectively).
The effects of rapamycin alone are summarized in
Fig. 1b. The lowest effective concentration of rapamycin
as a single agent after 24 h was 100 nmol/l for normoxic
cells (P= 0.011). Hypoxic cells were resistant to con-
centrations up to 500 nmol/l. The lowest effective con-
centration of rapamycin as a single agent after 48 h was
10 nmol/l for normoxic cells (P= 0.028) and 100 nmol/l for
hypoxic cells (P= 0.006). Analysis of variance found a
significant increase in cytotoxicity between doxorubicin
alone and doxorubicin+ 10 nmol/l rapamycin combina-
tions in both normoxic and hypoxic cells after 24 h
(P= 0.000 and 0.05, respectively), but this effect was
not observed at the later time points (Fig. 2).
Effects of doxorubicin and rapamycin on HIF-1α
induction
To determine the effect of these agents on the hypoxic
induction of HIF-1α, SDS-PAGE and Western Blotting
were carried out on nuclear extracts from HepG2 cells
exposed to doxorubicin or rapamycin when cultured
under normoxic or hypoxic conditions. As shown in
Fig. 3, 24 h exposure to hypoxic conditions resulted in a
significant increase in nuclear HIF-1α (P= 0.001). This
was confirmed using immunohistochemistry (Fig. 4).
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Although the doxorubicin treatment of 10 µmol/l had no
significant effect, the 50 µmol/l treatment significantly
reduced the amount of HIF-1α detected in the nucleus
(P= 0.002) (Fig. 3a). Doxorubicin treatment did not
result in the induction of HIF-1α in the nucleus of
normoxic cells (Fig. 3a). Both the 10 nmol/l rapamycin
and the 100 nmol/l rapamycin treatments significantly
inhibited the accumulation of HIF-1α in the nucleus of
hypoxic cells (P= 0.021 and 0.001, respectively)
(Fig. 3b).
Fig. 1
The effects of (a) doxorubicin and (b) rapamycin on the viability of HepG2 cells cultured under normoxic and hypoxic conditions. HepG2 cells were
seeded onto 96-well plates (1×104 cells/well) and incubated overnight. Plates were then exposed to doxorubicin or rapamycin and incubated for 24,
48 and 72 h under normoxic or hypoxic conditions. Cell viability was estimated using the MTS assay and normalized to untreated control. Data points
represent mean ±SEM from at least three independent experiments. For statistical analysis of doxorubicin treatments, analysis of variance with
Tamhane post-hoc comparisons was used; * denotes a significant decrease in cell viability compared with the control P<0.01. For statistical analysis
of rapamycin treatment, a one-tailed t-test was carried out; ** denotes a significant decrease in cell viability compared with the control P<0.05.
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Effects of doxorubicin and rapamycin drug-eluting beads
in a murine model of hepatocellular carcinoma
Consequent to the findings described above, the anti-
tumour effects of doxorubicin and rapamycin, both as
monotherapies and in combination, were evaluated
in vivo in a pilot study using a murine model of HCC
(Fig. 5). HepG2 tumour-bearing mice were treated with
doxorubicin-loaded beads, rapamycin-loaded beads,
rapamycin and doxorubicin co-loaded beads, oral rapa-
mycin and doxorubicin-loaded beads in combination with
Fig. 2
The effects of doxorubicin +10 nmol/l rapamycin on the viability of HepG2 cells cultured under (a) normoxic and (b) hypoxic conditions. HepG2 cells
were seeded onto 96-well plates (1×104 cells/well) and incubated overnight. Plates were then exposed to doxorubicin +10 nmol/l rapamycin and
incubated for 24, 48 and 72 h under normoxic or hypoxic conditions. Cell viability was estimated using the MTS assay and normalized to untreated
control. Data points represent mean±SEM from at least three independent experiments. For statistical analysis, analysis of variance was carried out.
*P<0.000, **P<0.05.
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oral rapamycin. At day 45, analysis of variance showed a
significant difference between the treatment groups
(P= 0.008). Post-hoc comparisons indicated that three
treatment regimens resulted in a significant reduction in
tumour volume compared with the control – doxorubicin-
loaded beads (P= 0.014), rapamycin and doxorubicin co-
loaded beads (P= 0.011) and oral rapamycin in combi-
nation with doxorubicin-loaded beads (P= 0.021).
Rapamycin monotherapies inhibited tumour growth for
the duration of the experiment and oral rapamycin
inhibited tumour growth more effectively than
rapamycin-loaded beads, although the pattern of growth
inhibition was the same for both treatments.
Doxorubicin-loaded beads inhibited tumour growth in a
manner similar to rapamycin-loaded beads up to day 32.
We found that doxorubicin was necessary and sufficient
for tumour regression, which occurred from day 32 in the
doxorubicin-loaded bead cohort and in the rapamycin
and doxorubicin co-loaded bead cohort. The most
effective treatment overall was the combination of
doxorubicin-loaded beads and oral rapamycin, which
resulted in almost total inhibition of tumour growth to
day 35, tumour regression from day 28 to 30 and day 42 to
45 and complete tumour destruction reported in one
animal by day 45. All treatments resulted in decreased
tumour weight compared with the control (Fig. 6). There
was evidence of increased antitumoural activity with
combination therapies compared with either treatment
alone, and all treatments were well tolerated.
Discussion and conclusions
Here, we have identified a doxorubicin concentration of
10 µmol/l that is effective against normoxic and hypoxic
HCC cells. This 10 µmol/l dose is commensurate with
concentrations of doxorubicin that are eluted from DC
Beads at distances of up to 350 and 600 µm [36–38].
Viable hypoxic cells have been observed at distances of
50–250 µm from the nearest blood vessel [39]; thus,
tissue penetration of doxorubicin is sufficient to target
hypoxic cells.
Hypoxia-induced mechanisms of resistance to doxor-
ubicin are likely to be multifactorial and include reduced
drug accumulation and increased drug efflux [40–42],
resistance to apoptosis [43], decreased levels of topoi-
somerase II [44,45] and a reduction in free radical-
dependent DNA damage [46]. Toxic effects that are
oxygen dependent are reduced in hypoxia [47].
Hypoxia protected cells from doxorubicin-induced cyto-
toxicity (48 and 72 h treatments) at concentrations 10, 25
and 50 μmol/l. The cytotoxicity of doxorubicin is because
of a number of different mechanisms, with the activation
of one mechanism potentially having an inhibitory effect
on other mechanisms and particular co-factors being
required for efficient cytotoxicity in some cases. For
example, doxorubicin is a topoisomerase II poison with
the intercalation of doxorubicin into cellular DNA at
higher drug concentrations itself potentially inhibiting
the binding of TOP2 to cellular DNA and decreasing
Fig. 3
Nuclear accumulation of hypoxia-inducible factor 1α (HIF-1α) after doxorubicin and rapamycin treatments. Normoxic and hypoxic HepG2 cells were
exposed to doxorubicin or rapamycin for 24 h. Nuclear extracts were fractionated on a 10% SDS-PAGE gel, transferred to a PVDF membrane and
probed with anti-HIF-1α antibodies. Proteins were visualized using chemiluminescence. The membrane was stripped and reprobed using antibodies
against the nuclear house-keeping protein Lamin B1. Protein levels were quantified using densitometry analysis. HIF-1α was normalized to Lamin. Fold
change compared with untreated hypoxic cells was calculated. Statistical analysis was carried out using a t-test. *P<0.05, **P<0.01.
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TOP2-mediated cytotoxicity [48]. The complex interplay
of these factors with hypoxia-induced cell survival
mechanisms could explain why a 10 μmol/l dose is more
effective than higher doses. In this study, only the
50 μmol/l dose of doxorubicin was shown to inhibit
hypoxia-induced nuclear accumulation of HIF-1α. In line
with this study, Potmesil et al. [49] reported that the
frequency of single-strand DNA breaks in mouse leu-
kaemia cells increased with doses of doxorubicin
between 0.2 and 20 μmol/l, then plateaued in normoxic
cells and declined in hypoxic cells until the concentration
was increased to 200 μmol/l. Extracellular pH levels are
also higher in hypoxic cells compared with normoxic cells
because of the Warburg effect, which reduces the pro-
portion of doxorubicin in the nonionized membrane-
permeable form and consequently causes a reduction in
the accumulation of doxorubicin into cells [50–52].
Different local doxorubicin concentrations will also
impact on this drug-partitioning effect and drug-efflux
mechanisms may also be more pronounced when the
drug is at higher concentrations.
We subsequently established that 10 nmol/l rapamycin
inhibited cell viability in normoxic cells, but that a con-
centration of 100 nmol/l was required to inhibit
cell viability in hypoxic cells. Combinations of 10 nmol/l
rapamycin with doxorubicin were more effective against
both normoxic and hypoxic HepG2 cells than either
treatment alone. A primary mechanism contributing
towards drug resistance is increased drug efflux because
of the upregulation of P-glycoprotein MDR1 [40,41].
Rapamycin has been reported to improve the uptake of
chemotherapeutics in multidrug-resistant cell lines
because of competitive inhibition as a result of a direct
interaction of rapamycin with Pgp [53–55].
To ascertain the possible effects of doxorubicin and rapa-
mycin on responses to hypoxia-induced survival pathways,
we investigated their effects on hypoxia-induced nuclear
Fig. 4
Immunohistochemistry staining for hypoxia-inducible factor 1 (HIF-1) in normoxic and hypoxic HepG2 cells. Cells were seeded onto chamber slides.
HepG2 cells were seeded onto chamber slides and incubated under normoxic conditions until confluence was 60%. The cells were then incubated
under either (a) normoxic conditions or (b) hypoxic conditions for 24 h. The cells were incubated overnight with antibodies to HIF-1α and then
incubated with the TRITC-conjugated secondary antibody. 4′,6-Diamidino-2-phenylindole staining was used to visualize the nucleus. Images are taken
at ×100 magnification. HIF-1α is absent in normoxic cells and present in hypoxic cells.
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accumulation of HIF-1. Doxorubicin of 50 µmol/l and
rapamycin of 10 and 100 nmol/l attenuated the stabilization
of HIF-1α under hypoxic conditions.
Consequent to the findings described above, the anti-
tumour effects of doxorubicin and rapamycin, both as
monotherapies and in combination in vivo, were eval-
uated in a murine model of HCC. Rapamycin mono-
therapies inhibited tumour growth for the duration of the
experiment. Doxorubicin was necessary and sufficient for
tumour regression. The most effective treatment overall
appears to be the combination of DOXDEB and oral
rapamycin, which resulted in almost total inhibition of
tumour growth to day 35, tumour regression from day 28
to 30 and day 42 to 45 and complete tumour destruction
reported in one animal by day 45. There was evidence of
increased antitumoural activity with combination thera-
pies compared with either treatment alone, and all
treatments were well tolerated. In agreement with our
findings, combinations of doxorubicin with mTOR inhi-
bition were found to be more effective than mono-
therapies in an orthotopic syngeneic rat HCC model [32]
and in an ectopic xenograft mouse model of prostate
cancer [33] and lung and cervical cancers [31]. If cancer
cells with a hypoxic phenotype as well as cancer cells
with a normoxic phenotype can be successfully targeted
by specific drug regimens, as has been indicated by the
data presented here, there is a possibility of improving
the outcome of patients with primary liver cancer, a dis-
ease that, at present, has a dismal prognosis.
Fig. 5
Antitumoural activity of doxorubicin and rapamycin treatments in a mouse model of hepatocellular carcinoma. In all, 5×106 HepG2 cells were
subcutaneously implanted in NMRI: nu/nu mice (day 0). Tumour was palpable at day 23 after implantation and treatment was initiated. Rapamycin was
administered by gavage at a dose of 1 mg/kg/day. 100 µl of beads loaded as specified was injected adjacent to the tumour. Tumour volume was
measured at days 23, 25, 28, 30, 32, 35, 37, 42 and 45. Data shown represent the mean value of three replicates per group ±SEM, apart from the
control group, where data represent the mean of two replicates ±SEM. Statistical analysis was carried out using analysis of variance analysis.
*P≤0.05; **P≤0.01. DOXDEB, doxorubicin-loaded beads; RAPADEB, rapamycin-loaded beads; RAPADOXDEB, doxorubicin and rapamycin co-
loaded beads.
Fig. 6
Effects of doxorubicin and rapamycin treatments on tumour weight at
day 45 in a mouse model of hepatocellular carcinoma. Mice were
euthanized at day 45, and the tumours were excised and weighed. Data
represent mean ±SEM. Because of the small sample sizes, statistical
analysis was not carried out. DOXDEB, doxorubicin-loaded beads; p.o.,
orally; RAPADEB, rapamycin-loaded beads; RAPADOXDEB,
doxorubicin and rapamycin co-loaded beads.
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